Surgical treatment of ulcerative colitis in the biologic therapy era

Table 1 Literature-based comparison of postoperative complication risk associated with preoperative use of infliximab

Ref.	Year	Non-IFX/IFX patients	Infectious complication			Non-infectious complication
			IFX group	Non-IFX group	OR (95% CI)	IFX group	Non-IFX group	OR (95% CI)
Selvasekar et al[13]	2007	254/47	13 (28%)	25 (10%)	3.50 (1.64-7.5)	16 (34%)	99 (39%)	0.81 (0.4-1.55)
Schluender et al[12]	2007	134/17	3 (18%)	11 (8%)	2.40 (0.6-9.63)	3 (18%)	26 (19%)	0.89 (0.24-3.33)
Kunitake et al[9]	2008	312/101	6 (6%)	32 (10%)	0.55 (0.22-1.36)	11 (11%)	17 (5%)	2.12 (0.96-4.69)
Mor et al[85]	2008	46/46	10 (22%)	1 (2%)	13.8 (1.82-105)	6 (13%)	6 (13%)	1.00 (0.3-3.37)
Ferrante et al[83]	2009	119/22	2 (9%)	29 (24%)	0.31 (0.07-1.141)	NR	NR	NR
Coquet-Reinier et al[84]	2010	13/13	NR	NR	NR	3 (23%)	4 (38%)	NR
Gainsbury et al[86]	2011	52/29	5 (17%)	14 (27%)	1.87 (0.46-7.57)	12 (41% )	16 (31%)	0.59 (0.19-1.87)

IFX: Infliximab; OR: Odd ratio; NR: Not reported; CI: Confidence interval.